Scholarlink

Background <p>Recombinant human luteinizing hormone (rLH) was originally introduced to supplement recombinant human follicle-stimulating hormone (rFSH) for controlled ovarian stimulation (COS) in patients with hypogonadotropic hypogonadism. Promising evidence is emerging regarding the efficacy of rLH in conditions which mimic hypogonadotropic hypogonadism; however, current data remain insufficient to draw definitive conclusions. The aim of the present multicentre observational study was to characterize the in vitro fertilization (IVF) population in which a fixed combination of rFSH/rLH is prescribed, and to analyse both point-specific and cumulative outcomes associated with its use.</p> Methods <p>This study was conducted across the Infertility Units of 5 different large public hospitals in northern Italy. All women who were referred to the 5 IVF Units between January 2018 and December 2023 to undergo either conventional IVF or intracytoplasmic sperm injection (ICSI) were reviewed. Only homologous in vitro fertilization cycles were included. Patients who were prescribed a fixed-ratio (2:1) combination of rFSH and rLH, were deemed eligible for study entry. Patients whose partners had severe forms of male infertility (i.e., men with sperm concentration &lt; 1000000/ml or who underwent surgical sperm retrieval) were excluded. The primary outcome was the cumulative live birth rate (cLBR) per oocyte retrieval defined as the number of deliveries with at least one live birth resulting from one initiated or aspirated IVF/ICSI cycle.</p> Results <p>Overall, 9,703 IVF/ICSI cycles were included in the study. The median female age was 39 [36–41] years. The main IVF indications were mixed infertility (28%), followed by reduced ovarian reserve (24%) and tubal factor (15%). Ovarian reserve markers showed a median AMH of 1.00 [0.55–1.80] ng/ml and a median AFC of 6 [4–9]. A LBR of 24% [95%CI: 23–25] per cycle and 27% [95%CI: 26–29] per oocyte retrieval and a CPR of 33% [95% confidence interval (CI): 32–34] per cycle and 38% [95%CI: 37–39] per oocyte retrieval were observed. No differences emerged in LBR and CPR when patients were divided according to baseline LH levels (&lt; 6 mIU/ml vs. ≥ 6 mIU/ml).</p> Conclusions <p>The present study showed that the fixed-ratio rFSH/rLH combination was primarily employed in AMA women with poor or very poor prognosis. Our data also suggest that baseline serum LH concentrations do not significantly impact clinical outcomes in patients undergoing COS with the fixed rFSH/rLH combination. Future research directions should include well-designed, real-world comparative studies involving large multicentre datasets and robust patient stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical use of recombinant human luteinizing hormone beyond hypogonadotropic hypogonadism: a multicenter descriptive analysis from five Italian fertility centers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Andrea Busnelli,
  • Paolo Emanuele Levi-Setti,
  • Valeria Stella Vanni,
  • Andrea Carosso,
  • Gianluca Gennarelli,
  • Ilario Candeloro,
  • Francesco Maria Fusi,
  • Anna Elisa Nicolosi,
  • Rossella Masciangelo,
  • Andrea De Rosa,
  • Letizia Li Piani,
  • Chiara Dallagiovanna,
  • Marco Reschini

摘要

Background

Recombinant human luteinizing hormone (rLH) was originally introduced to supplement recombinant human follicle-stimulating hormone (rFSH) for controlled ovarian stimulation (COS) in patients with hypogonadotropic hypogonadism. Promising evidence is emerging regarding the efficacy of rLH in conditions which mimic hypogonadotropic hypogonadism; however, current data remain insufficient to draw definitive conclusions. The aim of the present multicentre observational study was to characterize the in vitro fertilization (IVF) population in which a fixed combination of rFSH/rLH is prescribed, and to analyse both point-specific and cumulative outcomes associated with its use.

Methods

This study was conducted across the Infertility Units of 5 different large public hospitals in northern Italy. All women who were referred to the 5 IVF Units between January 2018 and December 2023 to undergo either conventional IVF or intracytoplasmic sperm injection (ICSI) were reviewed. Only homologous in vitro fertilization cycles were included. Patients who were prescribed a fixed-ratio (2:1) combination of rFSH and rLH, were deemed eligible for study entry. Patients whose partners had severe forms of male infertility (i.e., men with sperm concentration < 1000000/ml or who underwent surgical sperm retrieval) were excluded. The primary outcome was the cumulative live birth rate (cLBR) per oocyte retrieval defined as the number of deliveries with at least one live birth resulting from one initiated or aspirated IVF/ICSI cycle.

Results

Overall, 9,703 IVF/ICSI cycles were included in the study. The median female age was 39 [36–41] years. The main IVF indications were mixed infertility (28%), followed by reduced ovarian reserve (24%) and tubal factor (15%). Ovarian reserve markers showed a median AMH of 1.00 [0.55–1.80] ng/ml and a median AFC of 6 [4–9]. A LBR of 24% [95%CI: 23–25] per cycle and 27% [95%CI: 26–29] per oocyte retrieval and a CPR of 33% [95% confidence interval (CI): 32–34] per cycle and 38% [95%CI: 37–39] per oocyte retrieval were observed. No differences emerged in LBR and CPR when patients were divided according to baseline LH levels (< 6 mIU/ml vs. ≥ 6 mIU/ml).

Conclusions

The present study showed that the fixed-ratio rFSH/rLH combination was primarily employed in AMA women with poor or very poor prognosis. Our data also suggest that baseline serum LH concentrations do not significantly impact clinical outcomes in patients undergoing COS with the fixed rFSH/rLH combination. Future research directions should include well-designed, real-world comparative studies involving large multicentre datasets and robust patient stratification.